Drugs / pegylated recombinant human arginase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02089763 | Apr 2014 → Mar 2017 | hepatocellular carcinoma | Bio-Cancer Treatment International Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegylated recombinant human arginase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02089763 ↗ |
| Route | Intravenous | “Weekly intravenous PEG-BCT-100 at 2.7 mg/kg was given.” PMID 33856599 ↗ Apr 2021 |